Solid Biosciences

Solid Biosciences Current Assets

The Current Assets of Solid Biosciences (SLDB) as of Nov 16, 2026 is 205.46 M USD. In the previous year, Current Assets was 157.30 M USD — a change of 30.61% (higher).

Current Assets

205.46 MUSD

YoY

30.61%

Last updated:

Current Assets of Solid Biosciences is 2025 205.46 M USD. Current Assets of Solid Biosciences was 2024 157.30 M USD. It decreases by 30.61% higher compared to the previous year.

The Solid Biosciences Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
128.64 M USD
Jan 1, 2019
86.30 M USD
Jan 1, 2020
158.90 M USD
Jan 1, 2021
228.62 M USD
Jan 1, 2022
219.64 M USD
Jan 1, 2023
129.73 M USD
Jan 1, 2024
157.30 M USD
Jan 1, 2025
205.46 M USD
The Solid Biosciences Current Assets history
YEARCurrent AssetsYoY
205.46 MUSD+30.61%
157.30 MUSD+21.25%
129.73 MUSD-40.93%
219.64 MUSD-3.93%
228.62 MUSD+43.87%
158.90 MUSD+84.12%
86.30 MUSD-32.91%
128.64 MUSD+82.06%
70.66 MUSD+76.77%
39.97 MUSD-28.23%
55.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solid Biosciences Stock analysis

What does Solid Biosciences do? Solid Biosciences develops gene transfer therapies for Duchenne muscular dystrophy, focusing on SGT-001 and SGT-003, which address the genetic cause by delivering synthetic transgenes producing dystrophin-like proteins. The company also works on AVB-202 for Friedreichs ataxia and AVB-401 for BAG3-mediated dilated cardiomyopathy, alongside platform technologies like novel capsid libraries and dual gene expression for packaging multiple transgenes. Its programs target neuromuscular and cardiac conditions, with SGT-003 specifically designed for muscle-specific expression including cardiac and respiratory muscles. The company's revenue streams come from developing these therapies for clinical trials and potential future commercialization. Solid Biosciences' primary customers are patients with Duchenne muscular dystrophy, Friedreichs ataxia, and BAG3-mediated dilated cardiomyopathy, seeking treatments for these rare neuromuscular and cardiac conditions. The company's development programs are focused on creating therapies that address the underlying genetic causes, aiming to provide long-term solutions rather than symptomatic relief. Its platform technologies, such as dual gene expression, support the creation of more efficient gene transfer vectors for future therapies. The company's key products include SGT-001, SGT-003, AVB-202, and AVB-401, each targeting specific genetic disorders. SGT-003 is designed to produce dystrophin-like protein exclusively in muscles, including cardiac and respiratory muscles, while AVB-202 and AVB-401 target Friedreichs ataxia and dilated cardiomyopathy, respectively. Solid Biosciences generates revenue through the development and potential commercialization of these gene transfer candidates, with a focus on rare diseases where current treatments are limited. Solid Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solid Biosciences stock

Current Assets of Solid Biosciences is 205.46 M USD in 2025.

Current Assets of Solid Biosciences changed from 157.30 M USD to 205.46 M USD, representing a 30.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Solid Biosciences since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Solid Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Solid Biosciences

All Key Metrics — Solid Biosciences